An even more promising agent than celecoxib proved to be Licofelone (a COX-2/5-LOX inhibitor), which improved the therapeutic effect of a liposomal cancer vaccine (tyrosinase-­related protein 2 peptide with α-galactosylceramide) by limiting the inflammatory-induced immunosuppression and ­awakening of the immune defense against melanoma cells, in vivo. This evidence concerns the gene PTGS2 and melanoma.